Celltrion Inc
KRX:068270

Watchlist Manager
Celltrion Inc Logo
Celltrion Inc
KRX:068270
Watchlist
Price: 175 600 KRW -0.68% Market Closed
Market Cap: 36.4T KRW
Have any thoughts about
Celltrion Inc?
Write Note

Celltrion Inc
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Celltrion Inc
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Celltrion Inc
KRX:068270
Gross Profit
â‚©1.2T
CAGR 3-Years
2%
CAGR 5-Years
19%
CAGR 10-Years
17%
SK Bioscience Co Ltd
KRX:302440
Gross Profit
â‚©142.2B
CAGR 3-Years
14%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Green Cross Corp
KRX:006280
Gross Profit
â‚©463.9B
CAGR 3-Years
-2%
CAGR 5-Years
5%
CAGR 10-Years
5%
H
Hugel Inc
KOSDAQ:145020
Gross Profit
â‚©278.5B
CAGR 3-Years
15%
CAGR 5-Years
14%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Gross Profit
â‚©211B
CAGR 3-Years
31%
CAGR 5-Years
38%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Gross Profit
â‚©32.2B
CAGR 3-Years
N/A
CAGR 5-Years
82%
CAGR 10-Years
N/A
No Stocks Found

Celltrion Inc
Glance View

Market Cap
36.4T KRW
Industry
Biotechnology

Celltrion Inc. is a South Korean biopharmaceutical company that has made significant strides in the development and commercialization of biosimilars, monoclonal antibodies, and novel therapeutics. Established in 2002, the company has positioned itself as a key player in the global pharmaceutical landscape, particularly known for its commitment to making biological drugs more accessible and affordable. With a robust pipeline of products targeting conditions such as autoimmune diseases, cancer, and infectious diseases, Celltrion leverages state-of-the-art biotechnology and a strong emphasis on research and development. This focus not only enhances its product offerings but also champions the company’s mission of improving patient outcomes worldwide. As the global market for biosimilars continues to expand, driven by increasing healthcare costs and an aging population, Celltrion stands at the forefront, equipped with a solid operational framework and a strategic partnership approach. The company’s flagship products, like Remsima, a biosimilar to Remicade, have achieved notable success, gaining approval in numerous countries and establishing a strong revenue stream. With its plans to diversify its product portfolio, including innovative therapies in oncology, Celltrion is poised for growth. For investors, this translates into a promising opportunity to tap into a company that not only prioritizes innovation but also operates within a rapidly evolving market characterized by increasing demand for more affordable biologics.

Intrinsic Value
187 027.88 KRW
Undervaluation 6%
Intrinsic Value
Price

See Also

What is Celltrion Inc's Gross Profit?
Gross Profit
1.2T KRW

Based on the financial report for Jun 30, 2024, Celltrion Inc's Gross Profit amounts to 1.2T KRW.

What is Celltrion Inc's Gross Profit growth rate?
Gross Profit CAGR 10Y
17%

Over the last year, the Gross Profit growth was 14%. The average annual Gross Profit growth rates for Celltrion Inc have been 2% over the past three years , 19% over the past five years , and 17% over the past ten years .

Back to Top